PMID- 25247335
OWN - NLM
STAT- MEDLINE
DCOM- 20151026
LR  - 20221207
IS  - 1423-0313 (Electronic)
IS  - 0031-7012 (Linking)
VI  - 94
IP  - 3-4
DP  - 2014
TI  - The effect of IGF2BP2 gene polymorphisms on pioglitazone response in Chinese type 
      2 diabetes patients.
PG  - 115-22
LID - 10.1159/000363414 [doi]
AB  - BACKGROUND: Genome-wide association studies identified that insulin-like growth 
      factor 2 mRNA-binding protein 2 (IGF2BP2) genetic polymorphisms are related to 
      type 2 diabetes mellitus (T2DM) in several populations. This study aimed to 
      investigate whether the IGF2BP2 gene rs1470579 and rs4402960 polymorphisms were 
      associated with T2DM and pioglitazone efficacy in Chinese T2DM patients. METHODS: 
      A total of 281 T2DM patients and 111 healthy volunteers were enrolled to identify 
      the IGF2BP2 gene rs1470579 and rs4402960 polymorphisms; 86 patients were randomly 
      selected and given a 12-week pioglitazone treatment (30 mg/day). Fasting plasma 
      glucose, postprandial plasma glucose (PPG), glycated hemoglobin, serum 
      triglycerides (TG), total cholesterol, low-density lipoprotein cholesterol and 
      high-density lipoprotein cholesterol (HDL-C) were determined before and after 
      pioglitazone treatment. RESULTS: The results showed that the IGF2BP2 gene 
      rs1470579 and rs4402960 polymorphisms were associated with T2DM in a Chinese 
      population (OR = 2.002, 95% CI 1.170-3.426, p < 0.05; OR = 1.879, 95% CI 
      1.110-3.182, p < 0.05). The effect of pioglitazone on PPG (p < 0.05), TG (p < 
      0.01) and HDL-C (p < 0.05) was lower in patients with the rs1470579 AC+CC 
      genotypes than in AA genotype carriers. Its effect on PPG level was also lower in 
      patients with the GT+TT genotypes of rs4402960 than in patients with the GG 
      genotype (p < 0.05). CONCLUSIONS: The IGF2BP2 gene rs1470579 and rs4402960 
      polymorphisms were associated with T2DM and therapeutic efficacy of pioglitazone 
      in this Chinese population.
CI  - (c) 2014 S. Karger AG, Basel.
FAU - Zhang, Liu-Fu
AU  - Zhang LF
AD  - Department of Neurology, Hefei Binhu Hospital, Hefei First People's Hospital, 
      Hefei, PR China.
FAU - Pei, Qi
AU  - Pei Q
FAU - Yang, Guo-Ping
AU  - Yang GP
FAU - Zhao, Ying-Chun
AU  - Zhao YC
FAU - Mu, Yan-Fang
AU  - Mu YF
FAU - Huang, Qiong
AU  - Huang Q
FAU - Zhu, You-Ling
AU  - Zhu YL
LA  - eng
SI  - ChiCTR/CCC00000406
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140918
PL  - Switzerland
TA  - Pharmacology
JT  - Pharmacology
JID - 0152016
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (IGF2BP2 protein, human)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Thiazolidinediones)
RN  - 0 (Triglycerides)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
EIN - Pharmacology. 2014;94(3-4):198
MH  - Asian People/*genetics
MH  - Blood Glucose/analysis
MH  - Cholesterol/blood
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/*genetics
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pioglitazone
MH  - Polymorphism, Genetic
MH  - RNA-Binding Proteins/*genetics
MH  - Thiazolidinediones/pharmacology/*therapeutic use
MH  - Triglycerides/blood
EDAT- 2014/09/24 06:00
MHDA- 2015/10/27 06:00
CRDT- 2014/09/24 06:00
PHST- 2014/04/10 00:00 [received]
PHST- 2014/05/06 00:00 [accepted]
PHST- 2014/09/24 06:00 [entrez]
PHST- 2014/09/24 06:00 [pubmed]
PHST- 2015/10/27 06:00 [medline]
AID - 000363414 [pii]
AID - 10.1159/000363414 [doi]
PST - ppublish
SO  - Pharmacology. 2014;94(3-4):115-22. doi: 10.1159/000363414. Epub 2014 Sep 18.